Market Overview

Global Virus Network Adds Singapore Consortium as Newest Center of Excellence

Share:

The Global
Virus Network (GVN)
and the GVN-Singapore Center of Excellence,
comprised of 7 virology research intuitions led by Duke-NUS Medical
School, announced today the induction of the Singaporean coalition as
GVN's newest Center of Excellence. The GVN represents 42 Centers of
Excellence and 7 affiliates in 27 countries and comprises foremost
experts in every class of virus causing disease in humans.

The announcement was made by Prof. Robert Gallo, MD, Co-founder
and Scientific Director of the GVN, Prof. Linfa Wang, PhD,
Professor & Director of the Emerging Infectious Diseases Programme at
Duke-NUS and professor at the Duke Global Health Institute, and Prof.
Christian Bréchot, MD, PhD
, President of the GVN. Prof. Wang will be
Director of the GVN-Singapore Center of Excellence.

"Joining the seven institutions to form GVN's latest Center of
Excellence in Singapore was a terrific idea by Prof. Linfa Wang," said Gallo,
also The Homer and Martha Gudelsky Distinguished Professor in Medicine
and Co-founder and Director of the Institute of Human Virology at the
University of Maryland School of Medicine, a GVN Center of Excellence.
"Their combined expertise and location in Southeast Asia are integral to
connecting us to virus hotspots in Singapore and the surrounding region."

"Our established platforms from pathogen discovery, serological
investigation to pathogenesis, animal models, biocontainment (up to
ABSL3) challenge studies, and rapid biomarker assessment of
countermeasure agents strongly positions us in the region to play an
important role in all aspects of viral disease investigation," said Wang.
"We currently have a large DTRA-funded project in Southeast Asia and
have just been invited to help in the current investigation of the Nipah
virus outbreak in Kerala, India. Both initiatives serve as good examples
of what the GVN-Singapore Center of Excellence can contribute to global
and regional efforts in fighting and containing viral diseases."

"We look forward to GVN-Singapore making significant contributions in
many areas, especially in rapid responses to outbreaks," said Bréchot.
"It is not common that coalitions in countries come together to form a
regional GVN Center of Excellence, and we are delighted that this
terrific group of experts came together to become a strong member of the
GVN. Their combined research will contribute greatly to our network as
it encompasses pathogen biology, epidemiology, diagnostics,
pathogenesis, structural biology, animal models, counter measures such
as vaccines and therapeutics, and a One Health approach to emerging
infectious diseases."

The seven institutions comprising the GVN-Singapore Center of Excellence
include:

Duke-NUS Medical School is a collaboration between Duke
University and National University of Singapore. The program in Emerging
Infectious Diseases is one of the Signature Research Programmes in the
school with the mission to conduct cutting-edge infectious diseases
research that will enhance healthcare in Singapore and the region. Wang
will lead the GVN efforts for GVN Singapore and on behalf of Duke-NUS
Medical School.

Singapore Immunology Network (SIgN) was established in
2006 by the Agency for Science, Technology and Research (A*STAR). SIgN's
mission is to advance human immunology research, contribute scientific
knowledge and make innovative discoveries to improve lives and further
socio-economic growth. SIgN is committed to translate research findings
into clinical and commercial applications, in partnership with clinics
and industry. SIgN is home to more than 210 national and international
researchers and support staff led by 20 renowned Principal
Investigators. The current SIgN research activities are broadly
categorized into the areas of Infectious Diseases, Cancer and Immune
Dysfunctions, and supported by a strong in-house cluster of cutting-edge
technology platforms. Prof. Lisa Ng, PhD, Senior Principal
Investigator, will lead the GVN efforts on behalf of SIgN.

Environmental Health Institute (EHI) is the research arm
of Singapore's National Environment Agency (NEA) that conducts research,
surveillance and evidence-based risk assessment on infectious diseases
of environmental concern. The Institute hosts the World Health
Organization Collaborating Centre for Reference and Research of
Arboviruses and their Associated Vectors. The key thrust of the
Institute is to develop knowledge and advance cost-effective tools and
strategies to support public health operations and policies. Associate
Institute Prof. Lee Ching Ng, PhD, Director, will lead the GVN
efforts on behalf of the EHI.

National Public Health Laboratory (NHPL) is an accredited
laboratory under Singapore's Ministry of Health. The laboratory performs
testing for viruses of public health significance and receives clinical
specimens from public hospitals in the country for surveillance and
outbreak investigation. It is also responsible for detection of rare or
dangerous pathogens including potential biothreats. The facilities
enable virus isolation, sequencing, PCR, serology, bioinformatics and
electron microscopy. A BSL3 laboratory is used for RG3 agents. Associate Prof.
Raymond Lin, MBBS, FRCPA, MSc
, Head and Senior Consultant, will lead
the GVN efforts on behalf of the NHPL.

NUS Yong Loo Lin School of Medicine is the medical faculty
of the National University of Singapore and it is the oldest medical
school in Singapore. Established in 1905 to educate and train medical
professionals for Singapore, the NUS Yong Loo Lin School of Medicine is
a leading medical educational and research institution in Asia. Assoc.
Prof. Justin Chu, PhD
at the Department of Microbiology and
Immunology will lead the GVN efforts on behalf of the Yong Loo Lin
School of Medicine.

Lee Kong Chian School of Medicine (LKCMedicine), a
partnership between Nanyang Technological University, Singapore (NTU)
and Imperial College London (Imperial), is training a generation of
doctors who will put patients at the centre of their exemplary medical
care. The School's primary clinical partner is the National Healthcare
Group, a leader in public healthcare recognised for the quality of its
medical expertise, facilities and teaching. Named after local
philanthropist Tan Sri Dato Lee Kong Chian, the School, which was
officially opened by Singapore's Deputy Prime Minister Teo Chee Hean on
28 August 2017, is a model for innovative medical education and a centre
for transformative research. Assist. Prof. Dahai Luo, PhD, BSc
will lead the GVN efforts on behalf of the Lee Kong Chian School of
Medicine.

DSO National Laboratories is the national defense research
agency in Singapore. The Biological Defense Program is a core program
within the Defense Medical & Environmental Research Institute (DMERI).
The program performs R&D activities for the Singapore Armed Forces
(SAF), developing technical competencies in diagnostics and
countermeasures for a range of high risk high consequence pathogens for
military operations and national emergencies. Boon Huan Tan, PhD,
Director, will lead the GVN efforts on behalf of the DSO National
Laboratories.

The GVN is a global authority and resource for the identification and
investigation, interpretation and explanation, control and suppression,
of viral diseases posing threats to mankind. It enhances the
international capacity for reactive, proactive and interactive
activities that address mankind-threatening viruses and addresses a
global need for coordinated virology training through scholarly exchange
programs for recruiting and training young scientists in human and
animal virology. The GVN also serves as a resource to governments and
international organizations seeking advice about viral disease threats,
prevention or response strategies, and GVN advocates for research and
training on virus infections and their many disease manifestations.

The GVN, in partnership with the Fondation Mérieux (FM) and the
University of Veterinary Medicine Hannover (TiHo), will convene the 10th
International Global Virus Network Meeting
on Eradication and
Control of (Re-)Emerging Viruses in Annecy, France November 28-30. More
information can be found at www.gvn.org.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the
preparedness, defense and first research response to emerging, exiting
and unidentified viruses that pose a clear and present threat to public
health, working in close coordination with established national and
international institutions. It is a coalition comprised of eminent human
and animal virologists from 42 Centers of Excellence and 7 Affiliates in
27 countries worldwide, working collaboratively to train the next
generation, advance knowledge about how to identify and diagnose
pandemic viruses, mitigate and control how such viruses spread and make
us sick, as well as develop drugs, vaccines and treatments to combat
them. No single institution in the world has expertise in all viral
areas other than the GVN, which brings together the finest medical
virologists to leverage their individual expertise and coalesce global
teams of specialists on the scientific challenges, issues and problems
posed by pandemic viruses. The GVN is a non-profit 501(c)(3)
organization. For more information, please visit www.gvn.org.
Follow us on Twitter @GlobalVirusNews

View Comments and Join the Discussion!